Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $3,271,795.52 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Sharon Benzeno sold 154,768 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the completion of the transaction, the insider directly owned 221,278 shares in the company, valued at approximately $4,677,816.92. This represents a 41.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sharon Benzeno also recently made the following trade(s):

• On Friday, June 26th, Sharon Benzeno sold 11,034 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $21.00, for a total transaction of $231,714.00.

Adaptive Biotechnologies Price Performance

NASDAQ ADPT traded up $0.05 during trading hours on Tuesday, hitting $21.45. The company had a trading volume of 3,421,196 shares, compared to its average volume of 3,848,816. The firm’s 50 day moving average is $15.66 and its 200 day moving average is $15.74. Adaptive Biotechnologies Corporation has a fifty-two week low of $9.96 and a fifty-two week high of $21.64. The company has a market capitalization of $3.43 billion, a price-to-earnings ratio of -65.00 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. During the same quarter in the previous year, the firm posted ($0.20) earnings per share. The firm’s quarterly revenue was up 35.1% on a year-over-year basis. On average, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors have recently added to or reduced their stakes in ADPT. Caitong International Asset Management Co. Ltd bought a new position in Adaptive Biotechnologies during the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC increased its position in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. raised its stake in shares of Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at about $51,000. Finally, Strive Financial Group LLC bought a new position in shares of Adaptive Biotechnologies during the fourth quarter worth about $52,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ADPT has been the subject of several recent research reports. Morgan Stanley lowered their price objective on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Guggenheim upped their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday. BTIG Research reaffirmed a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. JPMorgan Chase & Co. cut their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Finally, Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.